- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Utah to Pay Public Employees to Fill Prescriptions For High-Cost Drugs in Mexico
The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
PEHP Health and Benefits, a division of Utah Retirement Systems, is a nonprofit trust that provides health benefits to Utah’s public employees, including county, city, school, and other public workers.
According to PEHP’s members’ website, the Pharmacy Tourism Program allows members who are not enrolled in Medicare the option to fill select drugs in Tijuana, Mexico, rather than in their local pharmacies. For members with certain plan types, medications are covered by the payer’s pharmacy benefit at no extra cost, and members are allowed to fill a 90-day supply.
The payer also arranges and pays for roundtrip airfare from Utah to San Diego, California, as well as car transportation across the US—Mexico border to a facility in Tijuana that will dispense the drugs. Finally, patients who take the option to travel to Mexico are also paid a cash reward of $500.
Among the drugs that qualify for the tourism program plan are biologics etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), and ustekinumab (Stelara). Notably, potentially cost-saving biosimilars for etanercept and adalimumab have been approved by the FDA, but none of the biosimilar options have launched because of patent protection for the originator products.
Other drugs that qualify for the plan are products that treat multiple sclerosis (including glatiramer acetate, dimethyl fumarate, fingolimod, interferon, and teriflunomide) as well as therapies to treat psoriasis (apremilast), osteoporosis (teriparatide) and cancer (abiraterone).
According to the Tribune, state representative Norman Thurston, a Republican representing Provo, said of the plan, “Why wouldn’t we pay $300 to go to San Diego, drive across to Mexico and save the system tens of thousands of dollars? If it can be done safely, we should be all over that.”
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
